On November 14, 2019, Verastem, Inc. (the "Company") issued approximately $62.9 million aggregate principal amount of 5.00% Convertible Senior Second Lien Notes due 2048 (the "Notes") pursuant to an indenture by and between the Company and Wilmington Trust, National Association, as trustee and collateral agent (the "Indenture") (Filing, 8-K, Verastem, NOV 14, 2019, View Source [SID1234551524]). The Notes were issued upon settlement of previously announced privately negotiated agreements with a limited number of investors who are accredited investors (within the meaning of Rule 501 promulgated under the Securities Act of 1933, as amended (the "Securities Act")) and/or qualified institutional buyers (as defined in Rule 144A under the Securities Act), pursuant to which such accredited investors and/or qualified institutional buyers exchanged approximately $114.3 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2048 (the "Existing Notes") for the Notes. Following the exchange, the aggregate outstanding principal amount of the Existing Notes is approximately $35.7 million.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Notes are the Company’s senior, secured obligations and will be senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the Notes, and equal in right of payment with the Company’s existing and future indebtedness that is not so subordinated. The Notes are structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. The Notes will pay interest at a rate of 5.00% per year, payable semiannually in arrears on May 1 and November 1 of each year, and will mature on November 1, 2048, unless earlier converted or repurchased. In addition, the Notes will have the terms as described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 12, 2019 (the "Prior Form 8-K"). The information set forth in the Prior Form 8-K is incorporated herein by reference.